Continuing Education Activity

Hybrid imaging with Positron emission tomography (PET/CT) is emerging as a powerful tool to assess the biochemical profile of cancerous tissues. It evaluates the morphology and function of cancers in one sitting, which has a decisive impact on their treatment planning. This activity focuses on the role of fluorodeoxyglucose (FDG) PET/CT in the detection, staging, and follow-up of gastrointestinal malignancies, highlighting the indications and techniques of scanning. Various pitfalls in image interpretation are emphasized, with suggestions for avoiding them. The role of gallium PET/CT in assessing neuroendocrine tumors has been explained. Furthermore, this activity summarises the interprofessional best practice strategies to enhance healthcare outcomes in gastrointestinal malignancies.

Objectives:

• Explain the basic principle of PET/CT imaging.
• Review the anatomy of the gastrointestinal tract.
• Outline the indications for PET/CT in gastrointestinal malignancies.
• Summarise the PET/CT findings in gastrointestinal cancers.

Introduction

Gastrointestinal malignancies are a group of heterogeneous neoplasms encompassing diverse biological and physical behavior. The management options for these tumors vary based on their location, cell type, and growth pattern. Early precise diagnosis and accurate staging are critical to instituting appropriate treatment. Recent advancements in the imaging techniques for evaluating solid and hollow viscous organs have enabled the non-invasive assessment of these tumors, although histopathology remains the gold standard. Despite these refinements, no single imaging modality provides sufficient information, and often multiple investigations are judicially combined to offer strength from one modality where the other is lacking.[1]

Positron emission tomography/Computerized tomography (PET/CT) is a hybrid molecular imaging technique that combines the functional imaging advantages of PET with anatomical imaging from CT. The cancerous cells of the gastrointestinal tract (GIT) demonstrate preferential glucose metabolism to lactate in both aerobic and anaerobic environments; a phenomenon called the Warburg effect.[2]

The energy produced through this pathway is insufficient to meet the demand of increasing growth resulting in a rise in their glucose requirement. The oncogenes on the cell structures and growth factors activated by malignant cells trigger glycolysis through upregulation of GLUT-1 transporters and cellular hexokinase, forming the biochemical basis of FDG-PET imaging.

Fluorine-18 labeled deoxyglucose (FDG) is an analog of glucose that accumulates in the cancerous cells but, unlike glucose, cannot be channeled towards ATP production. This entrapment of FDG in cancerous and some inflammatory cells is responsible for image production in PET scanning. The Gallium PET/CT imaging, in contrast, relies on overexpression of somatostatin receptors in the well-differentiated neuroendocrine tumors and thus offers an exquisite assessment of the selected primary neuroendocrine tumors and their metastases.[3]

Anatomy and Physiology

Esophagus and Gastroesophageal Junction (GOJ)

Optimum treatment planning of esophageal cancers requires an accurate description of cancer location in upper GI tumors, which is impossible without a clear understanding of the segmental esophageal anatomy. Anatomical levels for these cancers are reported relative to anatomical landmarks set by the American Joint Committee on Cancer staging system (AJCC). The esophagus is divided into four segments. This delineation is vital to ensure that the tumor is covered in its entirety in the radiotherapy field. If surgical resection is planned, the choice of approach is appropriate for the tumor's location. For the localization of gastroesophageal junction (GOJ) tumors, the Siewert-Stein classification divides these cancers into three groups based on their epicenter relative to GOJ. Regional lymph nodes for the esophagus include supraclavicular, peri-esophageal, and celiac nodes.[4]

Large Intestine

The large intestine extends from the cecum to the anal verge, where the stratified squamous epithelium of the anal canal meets the anal skin. For colorectal cancers, the relation of the tumor with peritoneal reflection has high prognostic implications as the involvement of the peritoneum makes it a T4a disease and increases the incidence of peritoneal metastases.[5]

The parietal peritoneum covering the abdominal wall reflects anteriorly on the cecum, ascending and descending colon as visceral peritoneum, leaving their posterior circumference uncovered. The transverse and sigmoid colon are near completely intraperitoneal except for the area along the route of mesenteric vessels. The reflection of the peritoneum on the pelvic structures forms the rectouterine pouch in females and rectovesical pouch in males and partially covers the pelvic sidewall on either side. The rectum is thus covered anteriorly and laterally by the peritoneum in the upper part and only anteriorly in the middle part. The lower part of the rectum is entirely free of the peritoneum.

The anal canal is the terminal part of the GI tract and extends from the anorectal junction above (where the rectum passes through the pelvic diaphragm) to the anal verge below. It approximately measures 4 cm and has two crucial muscle layers. The inner layer, which is the continuation of the GI tract's circular muscle, forms the internal sphincter. The outer layer from the downward continuation of the levator ani and puborectalis forms the external sphincter with a small inter-sphincteric space between the two.

Nodal metastases from the colon follow the mesenteric vessels to either the SMA origin in the right colonic tumors or the IMA origin in the left colonic tumors and can then involve the para-aortic nodes. Rectal tumors drain in the mesorectal nodes to the superior rectal artery nodes, and then along the root of sigmoid mesentery can reach para-aortic nodes. They can also drain into internal iliac nodes.

Anal cancer spread has a greater predilection for the lymphatic system than the bloodstream.[6] The cancers above the dentate line follow the drainage pathway of rectal tumors. The cancers below the dentate line drain into the external iliac system through inguinal and femoral nodes.

Neuroendocrine Tumors

The Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are a group of heterogeneous neoplasms that arise from embryonal neural crest cells. These can arise from virtually any part of the GI tract, but the small intestine is the most common location. These tumors can exhibit broad clinical behavior ranging from indolent, slow-growing to highly aggressive behavior. This clinical behavior correlates with their cellular proliferation rate measured through immunohistochemical staining of a unique Ki67 protein.

Based on the Ki67 index, these tumors are divided into three grades according to the European Neuroendocrine Tumour Society and World Health Organization 2010 Classification Systems for NETs. Grade 1 tumors are well-differentiated with a ki67 index of <2% and show indolent behavior. Grade 3 tumors are poorly differentiated with a ki67 index of >20% and show aggressive clinical behavior. The Grade 2 moderately differentiated tumors have a behavior and proliferation profile between these two extremes.[7][8]

Radiotracers for PET/CT Imaging

Fluorine-18 combined with deoxyglucose is the most common radiotracer used in PET/CT imaging. The activity detection comes from multiple collisions of a positron in the radioactive material with surrounding electrons in the biological environment until it loses its kinetic energy and combines with an electron to form a short-lived positronium molecule. The positronium eventually annihilates, converting all its mass into two gamma-ray photons, 511 KeV each, that travel 180 degrees in the opposite direction. If both annihilation photons are detected within a short time interval, it is called a coincidence event and assumed to have originated from positronium annihilation somewhere along the line drawn between the two points. This obviates the need for a physical lead collimator and results in much better sensitivity than SPECT imaging, as no extrinsic collimation is required.[9] 

For Gallium imaging, the conjugated version of octreotide is bound via 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA) molecule ligand to Gallium 68 radiotracer, which then effectively binds with somatostatin receptors (SSTR) expressed by well-differentiated neuroendocrine tumors. The more aggressive, poorly differentiated tumors may not show uptake on Gallium PET and can sometimes be better evaluated with FDG-PET due to less expression of SSTR and increased glucose metabolism.[10]

Indications

Evidence-based indications for the use of FDG-PET/CT for gastrointestinal tumors in the United Kingdom, as published by the UK Royal College of Radiologists in 2016, include the following:

For esophageal and gastroesophageal cancers, PET/CT is indicated for staging/ restaging if radical treatment is suitable, including for patients who have received neoadjuvant treatment. PET/CT is also indicated for evaluating suspected recurrence when other imaging is negative or equivocal. Further proposed indications include PET/CT in response assessment and radiotherapy planning.

For colorectal cancers, imaging with PET/CT is indicated for the staging of patients with synchronous metastases at presentation, for example, pulmonary and liver lesions. Further indications include restaging patients with recurrence, assessing treatment response, detecting recurrence with rising tumor markers, and/or clinical suspicion of recurrence with normal or equivocal findings on other imaging. Post-treatment, the evaluation of indeterminate presacral masses can also be done with PET/CT.

PET/CT is performed in anal cancer to stage selected patients for radical treatment. Further proposed indications include radiotherapy planning and response assessment.

For neuroendocrine tumors, FDG-PET/CT is indicated for the staging/restaging selected poorly differentiated tumors with normal or negative MIBG and octreotide scans. 68Ga-DOTA-NOC PET/CT  is indicated in the staging of well-differentiated NETs (grade 1 and 2), detecting unknown primary, and evaluating recurrence.

Contraindications

Imaging with PET/CT requires careful patient preparation. Poor glycaemic control, incomplete fasting, and insulin injection just before the scan can affect the biodistribution of radiotracer as glucose in the blood can compete with FDG on the GLUT-1 transporters, and a high level of insulin can divert a substantial amount of FDG to the skeletal muscles and adipose tissue through insulin-dependent GLUT-4 transporters.

Ideally, PET/CT should not be performed until at least >6 weeks after radiotherapy or surgery and >2 weeks after stent placement to avoid inflammatory uptake at the intervention site, potentially overestimating the disease.[11]

Patients with claustrophobia may require sedation. PET/CT is generally unsuitable for pregnant patients, and alternate means of evaluating disease should be arranged.

Breastfeeding mothers should avoid contact with the infant after the scan, and the general recommendation is to bottle feed the infant by a third person for up to 12 hours after the scan.[12][13]

Equipment

The radiopharmaceutical is prepared in cyclotrons and brought into the department in lead-lined containers early in the morning. The handling process requires exquisite care and diligence to avoid exposure to the staff and public. The radiotracer is injected through a tungsten syringe employed in a specialized carrier and is kept behind a lead screen.[14]

The PET/CT system comprises stand-alone PET and CT scanners housed in a single gantry. The patient bed is shared between the two scanners and moves smoothly from the PET to the CT component during image acquisition.

A scintillator absorbs ionizing radiation and converts the fraction of absorbed energy into photons of visible or ultraviolet light which can then be converted into electric signals through photodetectors. The typical PET scanner consists of thousands of inorganic scintillation crystals organized in blocks to form detector modules arranged in a ring configuration. The bismuth germanate (BGO) detectors have been traditionally used as scintillation crystals but are now replaced by lutetium oxyorthosilicate (LSO) detectors.[15] 

These crystals absorb the energy from annihilation events in the body (511 Kev energy) and create tens of thousands of visible wavelength photons proportional to the amount of energy deposited by the annihilation photon. Random coincidence is when two detected photons have come from two separate annihilation events. Scatter coincidence is when both photons are from the same event, but one or both have scattered. True coincidence is the detection of both photons from the same annihilation event.[16] 

These light photons are channeled to the coupled photodetectors. The most common photodetectors in PET are photomultiplier tubes (PMTs), which consist of vacuum tubes with photocathodes.[17] The light photons interact with the cathode to produce electrons which are then amplified to produce an electric signal proportional to the energy deposited by the PET photons.

The initially formed image is not perfect in any sense and is significantly affected by the attenuation of PET photons in the body, the variation in detector efficiency, and the recording of scattering and random events with true coincidences. Therefore, attenuation correction is carried by a CT scan performed simultaneously. The CT component also helps provide additional anatomical information lacking in nascent PET images.

The images are then represented quantitatively in terms of the radioactivity concentration, i.e., kBq/ml, which is then converted into a standardized uptake value (SUV) by normalizing to the patient weight and injected radioactivity.[18] This SUV measurement can quantify glucose metabolism from a particular tissue of the body.

• SUV (g/ml) = tracer uptake(kBq/ml) / (activity (MBq) / weight (kg))

Preparation

The patient preparation for FDG-PET is complex as FDG is a glucose analog and will be taken up by all the tissues that physiologically transport glucose. PET imaging provides functional assessment at the cellular level; therefore, it is prone to artifacts caused by the physiological increase in cellular activity. Control of the glycaemic level and avoidance of activity of the non-target areas of the body are vital to maximizing diagnostic yield.

1. Glycaemic control: Patients are required to fast for 4 to 6 hours prior to the scan to reduce competition between glucose and deoxyglucose at the level of GLUT-1 transporters. The insulin spike from eating can also divert glucose/ FDG to peripheral muscles through insulin-dependent GLUT-4 receptors. In diabetic patients, imaging is preferred in the early morning to make use of overnight fasting. For the above-described reasons, the insulin injection should not be given before the scan. The blood glucose level is checked before the scan to ensure that it is below 200mg/dl.[19]
2. Muscular activity: As part of routine preparation, patients must avoid exercise the day before and on the day of the procedure. Patients should stay relaxed at the time of scanning and avoid swallowing and speaking during the scan to prevent radiotracer uptake in the muscles of phonation.
3. Brown fat uptake: The brown fat, due to its ability to produce non-shivering thermogenesis, can take up FDG in the cold environment and thus can give false-positive PET interpretation. Therefore, it is essential to provide the patient with a warm ambiance to keep brown fat activity in control.
4. Hydration: Patients should be well hydrated to increase renal excretion of FDG and are further instructed to empty the bladder just before the scan to minimize activity in the pelvic area from the full bladder. The patients are directed to drink water after the scan to facilitate the excretion of radioactive material from the body. Caffeinated drinks are not recommended.[13]
5. Cannulation: The procedure is explained to the patients, and any questions are answered to minimize anxiety. Patients are then seated in a lead-lined room and preferentially cannulated with a butterfly infusion set to avoid radiation exposure to the staff members.
6. The vaccine status and injection sites are recorded to avoid false-positive pitfalls as local inflammation at the injection site can produce FDG avid reactive change in the draining lymph nodes, most commonly seen in the axilla with arm vaccines.[20]

Technique or Treatment

The recommended intravenous dose of F18 FDG for adults is 370-740 MBq and for children is 4 to 5 MBq/kg.[21] After injection, the patient is seated comfortably in a warm environment for one hour to allow FDG distribution in the body. Any radiotracer extravasation is recorded, and the patient is advised to empty the bladder just before scanning.

Imaging is generally performed without oral or IV contrast. The patients are routinely advised to drink water which can act as a negative contrast agent for GIT.

Once the patient is on the scanner bed, the image acquisition starts with a topogram to plan the scanning area. For GI cancers, the imaging is mostly performed from the base of the skull to the mid-thigh. The next step is the non-breath-hold CT scan. The patient bed then moves to the PET component of the scanner to complete the combined imaging. The first set of data comprises non-attenuation correction imaging, which then undergoes attenuation correction using CT scan images.[11] The attenuation-corrected (AC) PET data can produce MIP images or be fused with CT images to provide anatomical and functional assessment in all three dimensions.

The interpretation of PET/CT images is largely carried out through maximum standard uptake value (SUV max) measurements. This is a semiquantitative assessment that is partly affected by the general metabolic status of the individual. Therefore, the background mediastinal blood pool and hepatic SUV max are recorded as a reference.

There is no single SUV value that can reliably differentiate benign from malignant process.[22] As a general rule, the metabolic activity can be categorised into 4 levels:

• Low uptake= SUV max < 2.5
• Intermediate uptake= SUV max 2.5 to 5
• High uptake = SUV max > 5
• Intense uptake = SUV max > 10

Complications

PET/CT is a safe procedure. The radiation dose from a routine diagnostic F-18 FDG at 350 MBq is 6-7 mSv. The CT component of the study is a reasonably low dose ranging from 2 to 4 mSV If used only for attenuation correction to 3-10 mSV if used for both attenuation correction and localization. These values are lower than the contrast-enhanced diagnostic CT scan with a dose of 15 to 25 mSV.[23]

It is imperative to be aware of various false negative and false positive findings that can cause misinterpretation. Some of the examples are as follows:

False-positive PET CT

Respiration or patient movement can mismatch the CT and PET data in the fused images and lead to misinterpretation. This is especially problematic in abdominal imaging, where bowel movement can give the false impression of peritoneal disease due to misregistration of physiological bowel activity outside the bowel lumen. This can be prevented by looking at the non-attenuation correction (NAC) imaging in a tricky situation.

The brown fat uptake in cold ambiance, particularly in the supraclavicular regions, can be misinterpreted as lymph nodes. Correlation of all areas of uptake with CT images is helpful to differentiate solid lesions from low Hounsfield unit fatty tissue.

Radiotracer extravasation and post-vaccination status can produce reactive lymph node uptake in the ipsilateral axilla. Such events should be documented in the patient questionnaire to be reference ready at reporting.

Inflammatory uptake at the site of radiotherapy, surgery, or biopsy can produce false-positive interpretation; therefore, the timing of scan post-intervention is crucial to differentiate malignant disease from inflammation. Chemotherapy can cause reactive marrow hyperplasia with diffuse increased radiotracer uptake in the skeleton.[24]

False-negative PET CT

The tumors with mucinous components might not show an affinity for FGD due to low cellularity, lack of GLUT-1 transporters, and poor glucose metabolism.[25] Well-differentiated NET may not show high FDG uptake; therefore, Gallium PET is instead used for their assessment.

The artifacts from metallic and vascular stents and high activity from the distended urinary bladder can mask the adjacent small tumors. Similarly, metformin causes diffusely increased bowel activity, complicating the assessment of colon pathologies.[26] (Figure 1)

Clinical Significance

Esophageal Cancer

Following histological confirmation of malignancy, esophageal cancer is staged through TNM classification. While early tumors can undergo surgical resection with or without neoadjuvant therapy, chemoradiotherapy followed by surgery is the standard of care for locally advanced esophageal cancers.[27]

Esophageal cancers generally produce focal or segmental areas of increased FDG uptake compared to low diffuse uptake seen in esophagitis (Figure 1). The T staging of early tumors is better performed with endoscopic ultrasound (EUS) due to its ability to differentiate between esophageal wall layers. EUS can also assess the immediate peri-esophageal lymph nodes with confidence. Contrast-enhanced CT scan has a complementary role in this regard. For non-locoregional and distant lymph nodes, PET/CT is the most sensitive modality and thus has a central role in the primary staging of FDG avid esophageal tumors.

Between the two main histological subtypes of esophageal cancers, squamous cell carcinoma primarily involves the upper and mid esophagus and is strongly associated with alcohol consumption and smoking. It generally shows intense FDG uptake as opposed to adenocarcinoma, which predominates in the lower esophagus, has an association with reflux and smoking, and can show highly variable FDG uptake. The incidence of adenocarcinoma is on the rise, and it is now the commonest subtype of esophageal cancer.

The PET/CT report must include the location, length, and SUV max of the tumor; tumor length is an independent prognostic factor for overall survival.[28] The commonest sites of metastases from esophageal cancers include lungs, liver, bones, adrenal glands, and non-regional LNs.  Detection of occult metastasis through PET CT, not visible on conventional imaging, can avoid futile surgeries in patients not suitable for curative resection (Figure 2). The assessment of lung metastases is challenging with PET/CT due to the size of the individual lesions, which is often below the threshold (>1 cm) for PET characterization. Secondly, the non-breath-hold CT component of the PET is suboptimal for lung nodule assessment. Due to hepatic background activity, the sensitivity of PET/CT for liver metastases is also low, and if hepatic metastasectomy is planned, then preoperative MRI is essential.

PET/CT is an excellent modality to rule out new metastases or recurrence at distant sites after curative treatment of esophageal cancers. The PET/CT sensitivity to detect disease recurrence is high (pooled sensitivity estimate around 96%), but the specificity is low (pooled specificity estimate 78%) due to post-operative inflammatory change and radiation pneumonitis, giving false-positive results.[29] PET/CT scans have a role in response assessment and radiotherapy planning, but concrete evidence for their routine use is lacking.[30]

Colonic Cancer

The colonic cancers can produce focal intermediate to high intensity eccentric or short segment radiotracer uptake, but the assessment is challenging due to background physiological colonic uptake, bowel movement with misregistration, and FDG uptake in fecal matter. Diffuse high colonic uptake is often seen with metformin intake and can mask the underlying pathology.[31]

Adenocarcinomas show variable uptake but generally have high SUV max except for the mucinous variety, which shows poor FDG avidity due to low cellularity and scarce expression of GLUT-1 transporters.

PET/CT is not routinely performed to assess primary colorectal cancers and local lymph nodes due to poor spatial resolution of the PET photon detectors and limited inherent bowel contrast.[32] The peri colonic nodes can hide by the metabolic bloom of the primary tumor.[33] 

MRI is generally performed for the local staging of rectal cancer and CECT for the remaining colonic cancers. Metastatic disease is seen in 20% of colonic cancers at presentation.[34] PET/CT is indicated for assessing metastatic disease in advanced tumors, especially if their resection is contemplated. The commonest sites of metastases are the liver, lung, ovaries, and peritoneum. Traditionally, metastatic disease is managed with systemic chemotherapy, but there is increasing recognition of metastasectomy with curative intent due to evidence of improved survival (37 to 58%) in patients who undergo surgical resection, even for multiple metastases.[35][36][37] 

However, if surgery is considered for liver metastases, planning an MRI of the liver is mandatory. The lung metastases require assessment with a breath-hold CT scan for accurate quantification and characterization. The peritoneal metastases on PET/CT can show focal uptake or diffuse perihepatic curvilinear uptake, often correlated with CT findings of peritoneal nodules or fat stranding. Ascites is commonly associated with peritoneal disease, which may or may not show high FDG uptake.

PET/CT has an established role in detecting disease recurrence in patients with new clinical symptoms, abnormal exam findings, rising tumor markers, or indeterminate presacral lesion on conventional imaging. The differentiation between recurrent disease and post-therapy change can be challenging on PET/CT. Generally, high-intensity focal uptake that persists several months after surgery is concerning for residual or recurrent disease. Low-intensity, ill-defined uptake after surgery is expected and related to inflammatory change.[38] PET/CT is also helpful in detecting recurrence in lymph nodes and distant organs.

There is not enough data to support the definite role of PET/CT in assessing complete responders. In assessing response to liver-directed therapies like selective internal radiation therapy (SIRT), FDG-PET can be helpful as the metabolic response can be greater than the morphological response.[39]

Anal Cancer

Anal cancers are rare and account for less than 2% of large bowel malignancies, although their incidence is increasing over the past few years in developed countries.[40] The commonest cell type is squamous cell carcinoma (>70%) which is strongly linked with infection with high-risk human papillomavirus (HPV-16).[41] Combined chemoradiotherapy is curative in the majority of the patients, but patients with recurrence or local failure after chemoradiotherapy may undergo abdominoperineal resection.

Due to the very high FDG affinity of primary anal squamous cell cancer (SCC), PET/CT is routinely indicated in the primary staging of anal cancer to rule out lymph nodal and hematogenous metastases (Figure 3). The local staging of anal cancers is generally performed with MRI. Further proposed roles of PET/CT in anal cancer management include radiotherapy planning (especially with increasing consideration of intensity-modulated radiation therapy (IMRT)), response assessment, and detection of recurrence.[42]

Gastrointestinal Neuroendocrine Tumors

Advancements in imaging techniques for detecting neuroendocrine tumors could partly be responsible for their rising incidence.

The well-differentiated neuroendocrine tumors (G1, G2) and their metastases are primarily assessed with 68Ga DOTA NOC PET/CT due to their expression of somatostatin receptors (SSTR). Contrary to popular belief, even the most well-differentiated and indolent neuroendocrine tumors can metastasize (Figure 4). FDG-PET/CT is indicated in selected patients with poorly differentiated high-grade tumors (G3) as these tumors generally lack SSTR and demonstrate up-regulation of glucose metabolism, which can be mapped through FDG-PET/CT.[43] 

In some patients with metastatic neuroendocrine tumors, there can be mixed proliferation profiles at different disease sites, which often becomes apparent after receptor-targeted therapy; the gallium scan shows stable or regressive disease, but the CT component of the study shows an enlargement of some non-gallium avid areas of disease.[44] FDG-PET/CT in these patients can show increased uptake in these areas due to their aggressive metabolic profile, which differs from the gallium avid disease sites. PET/CT in this scenario can be helpful to select the site for tissue sampling for histological correlate.  

The knowledge of Ga68-DOTA peptide biodistribution is crucial for the accurate interpretation of pathological uptake sites. Normal radiotracer uptake is seen in the spleen, adrenal glands, pancreas, pituitary gland, liver, kidneys, thyroid, and salivary glands. Unlike FDG-PET/CT, the uptake in background soft tissue and muscles is minimal, improving the contrast of the pathologies against the background.

Enhancing Healthcare Team Outcomes

The diagnosis and management of gastrointestinal malignancies require a multidisciplinary approach. Upper and lower GI endoscopies are generally the first lines of investigation for suspected gastrointestinal malignancy. Due to significant advancements in surgery, chemotherapy, and radiotherapy, the overall survival from these cancers is on the rise. The judicial use of FDG-PET/CT in FDG avid gastrointestinal malignancies can reduce the risk of disease recurrence by accurately mapping the disease distribution and thus influencing the treatment strategy.

It has become more important to accurately stratify the patients who can benefit from curative resection because the failure of long-term survival with complete resection is often related to the failure to detect distant metastases at the time of surgery. This capability of PET/CT in detecting distant diseases justifies its use in the primary staging of FDG avid GI cancers. However, if the primary tumor is non-avid, the imaging is not reliable for assessing distant disease as the metastases are expected to match the metabolic profile of the primary tumor.

For patients undergoing neoadjuvant therapy, PET/CT can help assess poor responders and may alter management in this group of patients, although the exact time point of imaging and response criterion for PET/CT needs to be established with robust evidence through randomized control trials.

The same phenomenon by which 68Ga-DOTA-NOC PET/CT targets somatostatin receptors expressed by well-differentiated neuroendocrine tumors is exploited for transporting personalized molecular radiotherapy (MRT) to these tumors; the procedure is called peptide receptor radionuclide therapy (PRRT). In this procedure, gallium-68 is replaced by a therapeutic radiotracer (mostly Lutetium-177). Before instituting therapy, the disease is mapped through Gallium PET or octreotide imaging to select the patient suitable for treatment; for the procedure to be effective, the majority of the tumor sites have to take up radiotracer above that of the liver. After therapy, planar imaging is performed to confirm the adequate distribution of radiotherapy in the disease sites.[45] This palliative therapy regimen is being comprehensively researched to evaluate the survival benefits in a selected group of patients.